Tag: SVIN 2023
Tenecteplase deemed a safe and feasible adjunct to thrombectomy in ALLY...
Intra-arterial tenecteplase has demonstrated potential as a safe and feasible adjunct to mechanical thrombectomy in patients with acute ischaemic stroke caused by a distal...
Endovascular therapy under general anaesthesia linked to improved functional outcomes versus...
The multicentre, randomised SEGA trial has found that acute ischaemic stroke patients who receive endovascular therapy (EVT) under general anaesthesia experience better functional outcomes...
Brainomix targets US expansion following launch of 360 platform at SVIN...
Brainomix has heralded its continued US expansion with the launch of a full suite of US Food and Drug Administration (FDA)-cleared modules in its...
Tigertriever device produces high treatment-success rate in challenging ICAD stroke patients
Rapid Medical has announced new data demonstrating “excellent” first-pass treatment success using the Tigertriever device in complex ischaemic stroke patients with underlying intracranial atherosclerotic disease (ICAD)....
SVIN 2023 to champion innovation and inclusivity in “notable departure” from...
In a “notable departure” from prior iterations of the conference, this year’s Society of Vascular and Interventional Neurology (SVIN) annual meeting (16–18 November, Miami,...
